Allogene Therapeutics (ALLO) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$0.19.
- Allogene Therapeutics' EPS (Weighted Average and Diluted) rose 4062.5% to -$0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.98, marking a year-over-year increase of 3717.95%. This contributed to the annual value of -$1.32 for FY2024, which is 3673.44% up from last year.
- Per Allogene Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.19 for Q3 2025, which was up 4062.5% from -$0.23 recorded in Q2 2025.
- Allogene Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.01 during Q4 2021, with a 5-year trough of -$0.69 in Q1 2023.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.38 (2024), whereas its average is -$0.42.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first soared by 10092.59% in 2021, then crashed by 690000.0% in 2022.
- Allogene Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $0.01 in 2021, then plummeted by 6900.0% to -$0.68 in 2022, then increased by 25.0% to -$0.51 in 2023, then soared by 42.08% to -$0.3 in 2024, then skyrocketed by 35.68% to -$0.19 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.19 for Q3 2025, versus -$0.23 for Q2 2025 and -$0.28 for Q1 2025.